/
COR
$288.42+$5.44 (+1.92%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$55.1B
195M shares
52-week range
$244.82 – $377.54
33% from low
Sector
WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$154.34
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $167.94B | $179.59B | $189.89B | $213.99B | $238.59B | $262.17B | $293.96B | $321.33B |
| Cost of revenue | $163.83B | $175.06B | $185.10B | $207.72B | $230.99B | $254.42B | $285.26B | $311.19B |
| Gross profit | $4.11B | $4.53B | $4.79B | $6.27B | $7.60B | $7.76B | $8.70B | $10.14B |
| Gross margin | 2.4% | 2.5% | 2.5% | 2.9% | 3.2% | 3.0% | 3.0% | 3.2% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $1.65B | $1.87B | $2.02B | $2.68B | $2.75B | $2.45B | $3.04B | $3.65B |
| EBITDA | $1.87B | $1.65B | −$4.73B | $2.91B | $3.11B | $3.41B | $3.36B | $3.74B |
| Net income | $1.66B | $855.4M | −$3.40B | $1.54B | $1.70B | $1.75B | $1.51B | $1.55B |
| Net margin | 1.0% | 0.5% | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
| EPS (diluted) | 7.53 | 4.04 | -16.60 | 7.39 | 8.04 | 8.53 | 7.53 | 7.96 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $337.9B | $17.79 | $17.52–$17.88 | 7 |
| 2027 | $356.8B | $19.81 | $19.30–$20.25 | 8 |
| 2028 | $378.8B | $21.98 | $20.06–$24.54 | 3 |
| 2029 | $403.3B | $25.12 | $24.65–$25.57 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$706.42
Price
$288.42
Implied upside
+145%
Peer comparison
Cencora, Inc.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
www.cencora.com- Employees
- 51,000
- IPO / List date
- Apr 4, 1995
- HQ
- CONSHOHOCKEN, PA
Held by traders on TradeandTell
No one on the platform currently holds COR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 121,940 | $41.2M |
| Bridgewater Associatesas of 2026-03-31 | 14,227 | $4.5M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 0.81% ($2.35/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-15 | $0.6000 | 2026-06-01 |
| 2026-02-13 | $0.6000 | 2026-03-02 |
| 2025-11-14 | $0.6000 | 2025-12-01 |
| 2025-08-15 | $0.5500 | 2025-09-03 |
| 2025-05-16 | $0.5500 | 2025-06-02 |
| 2025-02-14 | $0.5500 | 2025-03-03 |
| 2024-11-15 | $0.5500 | 2024-11-29 |
| 2024-08-09 | $0.5100 | 2024-08-26 |
| 2024-05-09 | $0.5100 | 2024-05-24 |
| 2024-02-08 | $0.5100 | 2024-02-26 |
Recent trades on TradeandTell
No one on the platform has traded COR yet.
